A LT H 1 7 ( 2 0 1 4 ) A 7 1 9 -A 8 1 3 one that a new technology having the ICER smaller than L 0 should not be accepted if the incremental effectiveness of the new technology is greater than the amount of B max divided by N times L k . On the contrary, although the new technology cannot be accepted (i.e., L k > L 0 ) under the conventional single-threshold approach, it should be accepted if the incremental effectiveness of the new technology is smaller than the amount of B max divided by N times L k . ConClusions: Our approach offers multiple decision criteria for assessing a new health care technology with respect to the cost-effectiveness and its acceptability under the budget constraint. The theory which links single-ICER decision with budget impact has a potential to improve value-based decision making in government based on price-volume consideration of a new technology.PurPose: Evaluation of medical devices faces different challenges to that of the pharmaceutical drugs i.e., the approaches for cost-effectiveness modelling of pharmaceutical drugs are not suitable for evaluation of devices. For example, the value of a device goes beyond the health benefits (i.e QALYs) to the patient as it might include other aspects such as increased efficiency, patient dignity, etc. Similarly, traditional cost modelling techniques are not suitable for evaluation of devices. The costs are not evenly spread across time and depend on implementation strategies (i.e. parameters such as volume, scale, etc) and there is a need for a modelling framework that can output time profile of costs by stakeholder. Furthermore, the cost-effectiveness depends on the service setting (i.e. parameters such as volume and scale of deployment). Method: This presentation describes the lessons learnt while evlauating the cost-effectivess of diagnostic tests and devices. The details of the different projects are as follows a) Finanical modelling of telemonitoring for HF and COPD, b) Cost effectiveness of Cardiac Magnetic Resonance imaging for ischaemic cardiomyopathy, c) Cost-effectiveness of Telemonitoring technologies for congestive heart failure. result: A brief description of the context that makes HTA of medical devices of interest and characteristics of the devices that make them different from pharmaceutical drugs is detailed. An overview of current approaches of evaluating devices at different HTA bodies is provided. A taxonomy to represent the value of medical devices along with methods for incorporating patients' preferences with examples of specific case studies. Finally, a financial modelling framework for evaluating devices that provides time profile of costs by stakeholder. ConClusion: Cost-effectiveness evaluation of medical devices is quite different to that of pharmaceutical drugs. An overview of current methods for evaluation of devices and the issues involved are described along with a tentative framework proposal for cost-effectiveness modelling of devices.Methods of a survey research in health have recently been included in an e...